Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 402, Issue 10403, Pages 705-719
Publisher
Elsevier BV
Online
2023-06-26
DOI
10.1016/s0140-6736(23)01185-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
- (2023) Connor Enright et al. Journal of the Endocrine Society
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
- (2023) Marlene Chakhtoura et al. EClinicalMedicine
- Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
- (2023) Vanita R Aroda et al. LANCET
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
- (2022) Rashmi Shetty et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
- (2022) Mikhail N. Kosiborod et al. DIABETES OBESITY & METABOLISM
- Semaglutide for the treatment of overweight and obesity: A review
- (2022) Natasha Chidekel Bergmann et al. DIABETES OBESITY & METABOLISM
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
- (2022) Subodh Verma et al. EClinicalMedicine
- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
- (2021) Sean Wharton et al. INTERNATIONAL JOURNAL OF OBESITY
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
- (2021) Baptist Gallwitz et al. Frontiers in Endocrinology
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
- (2020) Mansoor Husain et al. Cardiovascular Diabetology
- Pharmacotherapy for Obesity—Trends Using a Population Level National Database
- (2020) Abbinaya Elangovan et al. OBESITY SURGERY
- Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
- (2020) Kristina Boye et al. DIABETES OBESITY & METABOLISM
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- Factors affecting weight loss variability in obesity
- (2020) Robert Dent et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obesity: global epidemiology and pathogenesis
- (2019) Matthias Blüher Nature Reviews Endocrinology
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- From C-Reactive Protein to Interleukin-6 to Interleukin-1
- (2016) Paul M Ridker CIRCULATION RESEARCH
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Missing data in clinical trials for weight management
- (2015) Bradley W. McEvoy Journal of Biopharmaceutical Statistics
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Biological mechanisms that promote weight regain following weight loss in obese humans
- (2013) Christopher N. Ochner et al. PHYSIOLOGY & BEHAVIOR
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now